Modeling Nonalcoholic Fatty Liver Disease in the Dish Using Human-Specific Platforms: Strategies and Limitations

被引：11

作者：

Rezvani, Milad ^{[1
,2
,3
,4
]}

Vallier, Ludovic ^{[3
,5
]}

Guillot, Adrien ^{[6
,7
,8
,9
]}

机构：

[1] Charite Univ Med Berlin, Dept Pediat Gastroenterol Nephrol & Metab Med, Berlin, Germany

[2] Cincinnati Childrens Hosp Med Ctr, Div Gastroenterol Hepatol & Nutr, Cincinnati, OH USA

[3] Berlin Inst Hlth, Ctr Regenerat Therapies BCRT, Berlin, Germany

[4] Berlin Inst Hlth, Clinician Sci Program, Berlin, Germany

[5] Max Planck Inst Mol Genet, Berlin, Germany

[6] Charite Univ Med Berlin, Campus Virchow Klinikum, Berlin, Germany

[7] Campus Charite Mitte, Dept Hepatol & Gastroenterol, Berlin, Germany

[8] Charite Univ Med Berlin, Campus Virchow Klinikum, D-13353 Berlin, Germany

[9] Campus Charite Mitte, Dept Hepatol & Gastroenterol, D-13353 Berlin, Germany

来源：

CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY | 2023年 / 15卷 / 05期

关键词：

Induced Pluripotent Stem Cells; Liver-on-Chip; Precision-Cut Liver Slices; Liver Organoids; PLURIPOTENT STEM-CELLS; PRECISION-CUT LIVER; CHOLANGIOCYTE ORGANOIDS; GENE-EXPRESSION; HEPATOCYTES; GENERATION; METABOLISM; EPITHELIUM; SLICES; MOUSE;

D O I：

10.1016/j.jcmgh.2023.01.014

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

This review article presents the latest research on nonal-coholic fatty liver disease (NAFLD) in vitro modeling. Ben-efits and limitations of using human induced pluripotent stem cell-derived approaches, primary organoids, liver-on-a-chip, and precision-cut liver sections are discussed to help researchers choose the most appropriate model.

引用

页码：1135 / 1145

页数：11

共 50 条

[1] Treatment strategies in nonalcoholic fatty liver disease
Tilg, H
Kaser, A
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2005, 2 (03): : 148 - 155
[2] Treatment strategies in nonalcoholic fatty liver disease
Herbert Tilg
Arthur Kaser
Nature Clinical Practice Gastroenterology & Hepatology, 2005, 2 : 148 - 155
[3] A Human Liver-on-a-Chip Platform for Modeling Nonalcoholic Fatty Liver Disease
Lasli, Soufian
Kim, Hon-Jun
Lee, Kan
Suurmond, Ceri-Anne E.
Goudie, Marcus
Bandaru, Praveen
Sun, Wujin
Zhang, Shiming
Zhang, Niyuan
Ahadian, Samad
Dokmeci, Mehmet R.
Lee, Junmin
Khademhosseini, Ali
ADVANCED BIOSYSTEMS, 2019, 3 (08)
[4] Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
Golabi, Pegah
Bush, Haley
Younossi, Zobair M.
CLINICS IN LIVER DISEASE, 2017, 21 (04) : 739 - 753
[5] Focus on Therapeutic Strategies of Nonalcoholic Fatty Liver Disease
Durazzo, Marilena
Belci, Paola
Collo, Alessandro
Grisoglio, Enrica
Bo, Simona
INTERNATIONAL JOURNAL OF HEPATOLOGY, 2012, 2012
[6] Lipidomics in human nonalcoholic fatty liver disease
Buechler, Christa
CLINICAL LIPIDOLOGY, 2014, 9 (03) : 279 - 282
[7] Preventive Strategies for Nonalcoholic Fatty Liver Disease After Liver Transplantation
Choudhary, Narendra S.
Saigal, Sanjiv
JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2019, 9 (05) : 619 - 624
[8] Quantitative modeling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease
Sen, Partho
Govaere, Olivier
Sinioja, Tim
McGlinchey, Aidan
Geng, Dawei
Ratziu, Vlad
Bugianesi, Elisabetta
Schattenberg, Jorn M.
Vidal-Puig, Antonio
Allison, Michael
Cockell, Simon
Daly, Ann K.
Hyotylainen, Tuulia
Anstee, Quentin M.
Oresic, Matej
ISCIENCE, 2022, 25 (09)
[9] Role of autoimmune phenomena in nonalcoholic fatty liver disease: Insights and limitations
Krishnan, Arunkumar
Mukherjee, Diptasree
WORLD JOURNAL OF HEPATOLOGY, 2025, 17 (03)
[10] Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease
Fedchuk, L.
Nascimbeni, F.
Pais, R.
Charlotte, F.
Housset, C.
Ratziu, V.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (10) : 1209 - 1222

← 1 2 3 4 5 →